The Generic Retribution The generic industry has always been overshadowed by branded pharmaceuticals. The government policies and the mandate have […]

October sees a frenzy of biotech IPOs October was the busiest month in three years for initial public offerings in

Venture Financing: Ready To Rebound? There’s little doubt that the financing window has opened up, but investors, analysts and biotech

Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new Wharton study comparing average prices

Gene Tests? Not So Fast The U.S. Food and Drug Administration Monday released draft guidelines regarding how genetic data could

States flock to biotech like gamblers to lottery tickets Florida lawmakers last month approved a $310 million biotech research center

In Initial Finding, FDA Calls Cloned Animals Safe as Food Milk and meat from cloned animals are safe to consume,

Biotech Startups: Take Your Time Until startups’ products are close to gaining approval, there’s no reason why smart investors would

Has the debate on GM crops been misleading? More than a hundred scientists have written to Tony Blair, complaining about

Are Adult Stem Cells a Bust? Opponents of research on embryonic stem cells have insisted that adult stem cells are